Breast Cancer

, Volume 17, Issue 4, pp 233–240

Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer

  • Mikihiro Kusama
  • Tadashi Nomizu
  • Kenjiro Aogi
  • Masataka Yoshimoto
  • Noboru Horikoshi
  • Toshio Tabei
  • Shinzaburo Noguchi
  • Shigeto Miura
  • Norio Yoshimura
  • Morihiko Kimura
  • Kazushige Toyama
  • Eisei Shin
Original Article

Abstract

Background

A multicenter, phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent 4-week regimen of capecitabine in patients with advanced/metastatic breast cancer.

Methods

Fifty patients who had received no more than one prior chemotherapy regimen for advanced/metastatic disease were enrolled from 23 centers and received at least two 4-weekly cycles of capecitabine (828 mg/m2 orally twice daily for 3 weeks followed by a 1-week rest period).

Results

The overall response rate assessed by the Independent Review Committee (standard population, n = 46) was 28.3% (95% confidence interval 16.0–43.5%), including complete responses in 6.5%. Stable disease was observed in 20 patients and maintained for more than 6 months in 10 patients. The median duration of response in 13 evaluable responders was 5.3 months. Among evaluable patients (n = 47), median time to disease progression was 5.1 months. Median overall survival was 20.2 months. The most common treatment-related adverse events (all grades) were hand–foot syndrome (66%), nausea (26%), stomatitis (22%) and diarrhea (20%). Grade 3/4 treatment-related adverse events were seen in 23 patients (46%). The most common grade 3/4 adverse events were lymphocytopenia (22%), hand–foot syndrome (18%) and hyperbilirubinemia (10%).

Conclusions

Although the target overall response rate was not reached, the Japanese intermittent 4-week regimen of capecitabine was shown to be an effective and well-tolerated first- or second-line therapy for advanced/metastatic breast cancer.

Keywords

Capecitabine Breast cancer Advanced Metastatic Efficacy Safety Four-week (Japanese) regimen 

References

  1. 1.
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998;55:1091–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–93.PubMedGoogle Scholar
  4. 4.
    Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, phase II study of oral capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14:1227–33.CrossRefPubMedGoogle Scholar
  7. 7.
    O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Stockler, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line therapy for advanced breast cancer (ABC). J Clin Oncol. 2007;25(18S):1031.Google Scholar
  11. 11.
    Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol. 2008;184(9):450–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Saeki T, Takashima S, Terashima M, Satoh A, Toi M, Osaki A, et al. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. Int J Clin Oncol. 2005;10:51–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Saeki T, Kimura T, Toi M, Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer. 2006;13:49–57.CrossRefPubMedGoogle Scholar
  14. 14.
    Japanese breast cancer society, general rules for clinical and pathological recording of breast cancer, 12th version, June 1996.Google Scholar
  15. 15.
    Osako T, Ito Y, Takahashi S, Tokudome N, Iwase T, Hatake K. Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer. Tumori. 2007;93(2):129–32.PubMedGoogle Scholar
  16. 16.
    Cao S, Lu K, Ishitsuka H, Rustum YM. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol. 1997;16:226a (abstract 795).Google Scholar
  17. 17.
    Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998;58:685–90.PubMedGoogle Scholar
  18. 18.
    Honda J, Sasa M, Moriya T, Bando Y, Hirose T, Takahashi M, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results. J Med Invest. 2008;55(1–2):54–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Jukkola-Vuorinen A, Asola R, Kokko R, et al Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Proceedings from the 2008 San Antonio Breast Cancer Symposium. Abstract 82.Google Scholar
  20. 20.
    Sakamoto J, Kondo Y, Takemiya S, Sakamoto N, Nishisho I, Clinical Study Group of Capecitabine. A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. Anticancer Drugs. 2004;15(2):137–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Matsumoto K, Iwata H, Sasaki Y, Saeki T, Aogi K, Masuda N, Noguchi S, Fujii H, Fujiwara Y. A phase II study of capecitabine in advanced or recurrent breast cancer relapsing after treatment with a taxane-containing therapy (abstract O-208). The 14th Annual Meeting of the Japanese Breast Cancer Society.Google Scholar

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Mikihiro Kusama
    • 1
    • 13
  • Tadashi Nomizu
    • 2
  • Kenjiro Aogi
    • 3
  • Masataka Yoshimoto
    • 4
    • 14
  • Noboru Horikoshi
    • 5
    • 15
  • Toshio Tabei
    • 6
  • Shinzaburo Noguchi
    • 7
  • Shigeto Miura
    • 8
    • 16
  • Norio Yoshimura
    • 9
  • Morihiko Kimura
    • 10
    • 17
  • Kazushige Toyama
    • 11
    • 18
  • Eisei Shin
    • 12
    • 19
  1. 1.Tokyo Medical UniversityTokyoJapan
  2. 2.Hoshi General HospitalFukushimaJapan
  3. 3.National Hospital Shikoku Cancer CenterMatsuyamaJapan
  4. 4.Cancer Institute HospitalTokyoJapan
  5. 5.Japanese Foundation for Cancer ResearchTokyoJapan
  6. 6.Saitama Prefectural Cancer CenterSaitamaJapan
  7. 7.Osaka UniversityOsakaJapan
  8. 8.Aichi Prefecture Cancer CenterNagoyaJapan
  9. 9.Kyoto Prefectural UniversityKyotoJapan
  10. 10.Gunma Prefecture Cancer CenterMaebashiJapan
  11. 11.Shizuoka Prefecture General HospitalShizuokaJapan
  12. 12.National Osaka HospitalOsakaJapan
  13. 13.Sinjyuku Breast Center Kusama ClinicTokyoJapan
  14. 14.International University of Health and Welfare, Mita HospitalTokyoJapan
  15. 15.Juntendo University School of MedicineTokyoJapan
  16. 16.Kamiiida Daiichi General HospitalNagoyaJapan
  17. 17.Ohta General HospitalOhtaJapan
  18. 18.Shizuoka Health Management CenterShizuokaJapan
  19. 19.Iseikai HospitalOsakaJapan

Personalised recommendations